Glucagon as a Hormone: Driving Peptide Drug Market Trends and Therapeutic Applications
Abstract: Glucagon, a 29-amino acid peptide hormone, primarily raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. Its therapeutic role in severe hypoglycemia and emerging applications in metabolic disorders drive peptide drug market trends, projected to exceed $50 billion by 2030. Key brands (e.g., GlucaGen, Baqsimi) differ in delivery (injectable vs. nasal) and stability. Nasal glucagon offers faster absorption but lower bioavailability. Product comparisons highlight purity (>98%), stability (lyophilized vs. liquid), and cold-chain logistics (2–8°C). Factory GMP certifications and FDA/EMA approvals ensure quality. Selection criteria include onset time, storage conditions, and patient compliance. Industry trends emphasize dual-action analogs and oral formulations, expanding therapeutic scope beyond diabetes.